The global market for spinal cord stimulation (SCS) devices expected to become $9.0 billion by 2027, growing at CAGR 13.8% over the forecast period, driven by rising aging population, introduction of novel SCS therapies, fast advancing SCS applications and technologies, leading to more effective and individualized treatment for patients.
- The global market for spinal cord stimulation products is expected to continue at the fastest growth with increasing competition among device manufacturers to develop innovative, and targeted therapies.
- Other factors driving the market growth included aging population and related diseases or injuries or trauma resulting in chronic, intractable pain (back and leg pain), and growing awareness and usage of SCS technologies.
Technological trends and innovations are expanding to include pain indications (peripheral nerve targets), customizing and broadening pain coverage and precision, miniaturization and less invasive technologies, elimination of paresthesia or muscle weakness, lowering associated risks, improving ease of use or implantation, greater patient monitoring and tracking, and providing sustained pain relief.
According to International Association for the Study of Pain (IASP), neuropathic pain is caused by a lesion or disorder of the somatosensory nervous system.
- According to the Centers for Disease Control and Prevention (CDC), chronic pain afflicts more than one billion people worldwide, creating the need for safer and more effective pain therapy.
- Chronic pain affects 7–10% of the general population, entailing an overall physical and psychological burden more relevant than that seen with nociceptive pain. It affects up to 20% of the population in developed nations.
- According to the National Center for Health Statistics (NCHS), the annual costs of treating pain are more than the annual costs of treating cancer, diabetes and heart disease together.
Spinal cord stimulation is a pain-relief technique that delivers a low-voltage electrical current continuously to the spinal cord to block the sensation of pain.
- SCS is the most commonly used implantable neurostimulation technology for management of pain syndromes. As many as 50,000 neurostimulators are implanted worldwide every year.
- Cost-efficacy studies show that despite significant initial costs, SCS compared with other conventional treatments available to chronic pain patients results in long-term reductions in healthcare costs, which offset the high initial treatment costs over time.
The present therapeutic alternative considered as the gold standard for many kinds of chronic neuropathic pain is epidural spinal cord stimulation.
- The SCS devices as well as emerging peripheral nerve stimulators, are seen as viable non-addictive alternatives to treat everything from cancer pain to arthritis, back pain, migraines and peripheral neuropathy.
- The US-FDA requires labeling the recent advanced iterations of SCS systems. SCS is a widely accepted, FDA-approved medical treatment for chronic pain of the trunk and limbs (back, legs and arms).
- SCS is reported as a safe procedure due to its reversible and minimally invasive characteristics. SCS or dorsal column stimulation constitutes an advanced neuromodulation procedure able to actually decrease neuropathic pain in many syndromes such as in failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS) type I and II, postherpetic neuralgia and pure radicular pain.
The global spinal cord stimulation devices market research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).
The global spinal cord stimulation devices market segmented by product (rechargeable SCS device, non-rechargeable SCS device); application (degenerative disk disease, failed back syndrome, multiple back operations, unsuccessful disk surgery, complex regional pain syndrome, arachnoiditis or lumbar adhesive arachnoiditis); end user (hospitals, ambulatory surgery centers) and geography.
The global market for spinal cord stimulation devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.
- Geographically, the North America region accounted for the largest SCS market, followed by Europe, driven by recent and anticipated regulatory approval of new devices, rising demand for pain management solutions from aging and obese population, and rapid adoption of new products as an alternative therapy.
- On the other hand, the Asia Pacific and Latin America regions are expected to witness good market growth during the next few years. owing to high unmet needs, improving healthcare infrastructure and increasing cases of spinal cord-related injuries and disorders.
In addition, the global spinal cord stimulation devices market report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
- The SCS devices used for treating debilitating chronic back or leg pain, is expanding by a double-digit growth, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all eyeing to gain more market share with their respective technologies.
- Abbott has its Proclaim spinal cord stimulation and dorsal root ganglion systems, the Prodigy MRI spinal cord stimulation system and the Infinity deep brain stimulation system in the market. The company also received FDA approval for its Proclaim XR spinal cord stimulator for treating patients with persistent neuropathic pain.
- Medtronic is already the largest vendor of implantable SCS devices, which markets the Intellis platform as the world’s smallest implantable neurostimulator.
- Boston Scientific markets its “all-in-one” personalized and flexible spinal cord stimulation device, Spectra WaveWriter through a combination of different waveforms for treating leg and lower-back pain.
- The upcoming startup, Nevro has gained significant share recently, with the introduction of its Senza SCS system, a next-generation high-frequency waveform technology that has shown promise in treating back and leg.
- Saluda Medical is developing its Evoke ECAP-Controlled closed-loop spinal cord stimulation system for pain management.
Major competitors operating in the global spinal cord stimulation systems market and profiled in this report include Abbott Laboratories, Inc., Boston Scientific Corp., Medtronic plc, Nevro Corp., Saluda Medical Pty Limited, and Stimwave Technologies, Inc.
- Rechargeable SCS Device
- Non-rechargeable SCS Device
- Degenerative Disk Disease (DDD)
- Failed Back Syndrome (FBS)
- Multiple Back Operations
- Unsuccessful Disk Surgery
- Complex Regional Pain Syndrome (CRPS)
- Arachnoiditis or Lumbar Adhesive Arachnoiditis
- End User
- Ambulatory Surgery Centers (ASCs)
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- Abbott Laboratories, Inc.
- Boston Scientific Corp.
- Medtronic plc
- Nevro Corp.
- Saluda Medical Pty Limited
- Stimwave Technologies, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/